Study guide

PDR, macular oedema and diabetic trials

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

PDR, macular oedema and diabetic trials

Key Takeaways Explain This Topic AI

PDR involves neovascularization with risks of haemorrhage and tractional detachment.

Macular-oedema treatment depends on centre involvement, vision, anatomy, pressure and treatment burden.

DRS, ETDRS and DRCR trials answer different questions with specific populations and follow-up periods.

Last updated: October 2026

Proliferative Diabetic Retinopathy (PDR)

Proliferative diabetic retinopathy is defined by the proliferation of fragile extraretinal new vessels (neovascularisation) that penetrate the internal limiting membrane (ILM) to arborize along the posterior hyaloid interface or scaffold onto the cortical vitreous.

Neovascularisation of the Disc (NVD): New abnormal vessels located on the optic nerve head or within one disc area (1 DD) of the disc margin.

Neovascularisation Elsewhere (NVE): New abnormal vessels located more than one disc area from the optic nerve head margin.

The DRS High-Risk PDR Criteria

The landmark Diabetic Retinopathy Study (DRS) established the formal definition of High-Risk PDR , which mandates immediate panretinal photocoagulation (PRP) or anti-VEGF therapy to prevent severe visual loss:

NVD ≥ 1 / 4 \ge 1/4 ≥ 1/4 to 1 / 3 1/3 1/3 disc area (even in the complete absence of vitreous or preretinal haemorrhage);

Any NVD (regardless of area) accompanied by acute vitreous haemorrhage or preretinal (subhyaloid) haemorrhage;

NVE ≥ 1 / 2 \ge 1/2 ≥ 1/2 disc area accompanied by acute vitreous haemorrhage or preretinal haemorrhage.

Diabetic Macular Oedema (DMO): Definitions, Classification & Biomarkers

Diabetic macular oedema is the principal cause of visual acuity decline in patients with diabetic retinopathy, occurring in both NPDR and PDR.

Center-Involving vs. Non-Center-Involving DMO

Modern clinical management has transitioned from historical biomicroscopic definitions to high-resolution Spectral-Domain Optical Coherence Tomography (SD-OCT):

Center-Involving DMO (CI-DMO): Characterized by retinal thickening, intraretinal cystoid spaces, or subretinal neurosensory fluid involving the central 1-mm foveal subfield. On OCT thickness maps, CI-DMO is defined by central subfield thickness (CST) exceeding normative machine-specific thresholds:

Heidelberg Spectralis: ≥ 305 μ m \ge 305\,\mu\text{m} ≥ 305 μ m in women; ≥ 320 μ m \ge 320\,\mu\text{m} ≥ 320 μ m in men;

Zeiss Cirrus: ≥ 290 μ m \ge 290\,\mu\text{m} ≥ 290 μ m in women; ≥ 305 μ m \ge 305\,\mu\text{m} ≥ 305 μ m in men.

Non-Center-Involving DMO (NCI-DMO): Retinal thickening or hard exudate rings situated within the ETDRS macular grid but sparing the central 1-mm foveal subfield.

Historical ETDRS Clinically Significant Macular Oedema (CSMO)

Prior to optical coherence tomography, the ETDRS defined CSMO solely based on contact lens slit-lamp biomicroscopy. The presence of any one of the following three features fulfilled the diagnosis of CSMO:

Retinal thickening situated within 500 μ m 500\,\mu\text{m} 500 μ m of the center of the macula ;

Hard exudates situated within 500 μ m 500\,\mu\text{m} 500 μ m of the center of the macula , provided they are accompanied by adjacent retinal thickening (which may itself lie outside the 500 μ m 500\,\mu\text{m} 500 μ m zone);

A zone of retinal thickening ≥ 1 \ge 1 ≥ 1 disc area in size , any portion of which is situated within 1 disc area ( 1500 μ m 1500\,\mu\text{m} 1500 μ m ) of the center of the macula .

OCT Morphological Patterns and Prognostic Biomarkers

Cross-sectional SD-OCT resolves three distinct morphological manifestations of DMO:

Spongiform / Diffuse Retinal Thickening: Diffuse inner and outer retinal swelling with reduced optical reflectivity, representing intracellular cytotoxic oedema of Müller cells.

Cystoid Macular Oedema (CMO): Well-defined, hyporeflective round or oval spaces primarily within the inner nuclear layer (INL) and outer plexiform layer (OPL), caused by extracellular fluid pooling and Müller cell septal rupture.

Subretinal Neurosensory Detachment: Accumulation of hyporeflective serous fluid between the photoreceptor outer segments and the apical RPE surface, observed in approximately 15–30% of eyes with severe DMO.

Two critical prognostic imaging biomarkers must be evaluated on baseline SD-OCT:

Disorganization of Retinal Inner Layers (DRIL): The inability to demarcate the boundaries separating the ganglion cell layer-inner plexiform layer (GCL-IPL) complex, the inner nuclear layer (INL), and the outer plexiform layer (OPL). DRIL is associated with disruption of bipolar, amacrine, and horizontal cell synaptic architecture. Extensive horizontal DRIL ( > 500 μ m >500\,\mu\text{m} > 500 μ m ) correlates strongly with poor visual recovery despite complete anatomical resolution of fluid.

Hyperreflective Foci (HRF): Small ( < 30 μ m <30\,\mu\text{m} < 30 μ m ), discrete, punctate intraretinal lesions with reflectivity equal to or exceeding the RPE band, lacking posterior optical shadowing. HRF have several possible substrates, including inflammatory cells and lipid. They are not a validated standalone basis for choosing steroid treatment.

Landmark Clinical Trials & Evidence-Based Therapeutics

Clinical Trial / Protocol Study Cohort & Comparison Arms Primary Findings & Clinical Impact

ETDRS (Early Treatment Diabetic Retinopathy Study) Evaluated focal/grid argon laser vs. observation for CSMO Focal laser to leaking microaneurysms and grid laser to appropriate areas of retinal thickening reduced the 3-year risk of moderate visual loss ( ≥ 15 \ge 15 ≥ 15 letters) by 50% (from 24% down to 12%). Defined standard laser parameters.

DRS (Diabetic Retinopathy Study) Evaluated panretinal photocoagulation (PRP) vs. observation in PDR Panretinal photocoagulation (1200–1600 burns, 500 μ m 500\,\mu\text{m} 500 μ m spot size) reduced the 2-year incidence of severe visual loss ( < 5 / 200 <5/200 < 5/200 ) in high-risk PDR by 50% (from 28% down to 14%).

DRCR.net Protocol T Evaluated intravitreal aflibercept (2.0 mg) vs. ranibizumab (0.3 mg) vs. bevacizumab (1.25 mg) in CI-DMO Baseline VA 20/40 or better: No significant between-agent difference was demonstrated in that subgroup (~+8 letters at 1 year). Baseline VA 20/50 or worse: Aflibercept was statistically and clinically superior (+18.9 letters) compared to ranibizumab (+14.2 letters) and bevacizumab (+11.8 letters) at 1 year.

DRCR.net Protocol S Evaluated ranibizumab (0.5 mg) vs. PRP for proliferative diabetic retinopathy Ranibizumab was non-inferior to PRP at 2 and 5 years for visual acuity, with less peripheral visual field loss, reduced rates of DMO, and fewer vitrectomies, though requiring continuous, intensive monitoring and repeated injections.

DRCR.net Protocol W Evaluated aflibercept vs. sham in severe NPDR without CI-DMO Prophylactic aflibercept significantly reduced the development of PDR and CI-DMO over 4 years, but showed no significant visual acuity benefit over observation followed by prompt treatment upon development of PDR/DMO.

Intravitreal Corticosteroid Implants

Intravitreal steroids downregulate VEGF gene expression, inhibit leukostasis, stabilize endothelial tight junction claudins, and suppress inflammatory cytokines (IL-6, TNF- α \alpha α ):

Intravitreal steroid implants may be considered for selected DMO, including pseudophakic eyes or insufficient/unsuitable other treatment according to the local label. Cataract and pressure elevation are important risks. A recent cardiovascular event or vitrectomy does not automatically prohibit anti-VEGF or mandate steroids. Consider glaucoma, capsule integrity, migration risk, patient goals and monitoring. Different implants have different release profiles and authorisations.

Indications for Pars Plana Vitrectomy (PPV) in Diabetic Retinopathy

Surgical intervention with 23-, 25-, or 27-gauge pars plana vitrectomy is indicated in advanced diabetic vitreoretinopathy for:

Non-clearing vitreous haemorrhage: Indicated after 1 to 3 months of observation in type 2 diabetes, or earlier (within 2 to 4 weeks) in type 1 diabetes, bilaterally affected individuals, or monocular patients.

Tractional Retinal Detachment (TRD): Recent or progressive fibrovascular traction involving or directly threatening the fovea.

Combined Tractional and Rhegmatogenous Retinal Detachment (TRRD): Caused by fibrovascular contraction tearing the ischaemic, atrophic retina near a vascular arcade.

Dense, persistent premacular subhyaloid haemorrhage: Trapped retrohyaloid blood over the fovea predisposing to permanent macular epiretinal membrane formation.

Refractory DMO with vitreomacular traction (VMT) or taut posterior hyaloid face: Relieves anteroposterior and tangential mechanical traction.

Systemic Care and Evidence Boundaries

DCCT in type 1 diabetes and UKPDS in type 2 established the value of systemic glycaemic management; blood-pressure and renal care also influence retinopathy risk. Coordinate control rather than treating the retina in isolation. Rapid metabolic improvement and pregnancy can require closer ophthalmic surveillance. Screening intervals follow disease and the local programme, and symptomatic change requires assessment outside screening.

Protocol T results depend on baseline acuity and time point: aflibercept outperformed both comparators in the worse-vision subgroup at one year, but its two-year advantage over ranibizumab was not statistically significant. Protocol V supports initial observation with rescue criteria in selected centre-involving DMO with good acuity and reliable follow-up. Protocol S supports anti-VEGF as an alternative to PRP in selected PDR, with sustained follow-up critical; missed injections can be dangerous. DRVS supported early vitrectomy in selected severe vitreous haemorrhage, especially type 1 diabetes, but modern timing depends on traction, retinal visibility, vision and other eye status rather than a fixed waiting period.